刍议培菲康联合四联疗法治疗幽门螺杆菌相关性慢性胃炎对胃黏膜组织肿瘤坏死因子-α的影响

Discussion on the Effect of Peifeikang Combined with Quadruple Therapy in the Treatment of Helicobacter Pylori-related Chronic Gastritis on Tumor Necrosis Factor-αin Gastric Mucosa

目的评判培菲康+四联疗法对幽门螺杆菌相关性慢性胃炎患者治疗的效果。方法随机选取该院2016年10月—2019年10月收治的80例幽门螺杆菌相关性慢性胃炎患者,依据患者入院编号情况分组,分为甲组入院编号单数40例,乙组入院编号双数40例。甲组采取培菲康+四联疗法治疗,乙组采取四联疗法治疗,比较甲组、乙组临床效果的差异性。结果甲组的治疗总有效率为80.0%,高于乙组的治疗总有效率57.5%,差异有统计学意义(χ^(2)=4.713,P<0.05)。甲组的Hp根除率为85.0%,高于乙组Hp根除率65.0%,差异有统计学意义(χ^(2)=4.267,P<0.05)。治疗前,甲组和乙组的胃黏膜组织TNF-α分别为(1.47±0.31)、(1.49±0.33)ng/mL,差异无统计学意义(t=0.279,P>0.05);治疗后甲组、乙组胃黏膜组织TNF-α分别为(0.66±0.15)、(1.03±0.26)ng/mL,差异有统计学意义(t=7.795,P<0.05)。结论慢性胃炎患者接受培菲康+四联疗法治疗的效果较佳,且能提高Hp根除率、改善患者胃黏膜组织TNF-α,值得在临床方面加以应用与推广。

Objective To evaluate the effect of Peifeikang+Quadruple Therapy on the treatment of patients with Helicobacter pylori-related chronic gastritis.Methods Randomly selected 80 patients with Helicobacter pylori-related chronic gastritis in the hospital from October 2016 to October 2019,group auordrg to patient admission number,and divided them into group A with an odd admission number of 40 and group B with an even admission number of 40.Group A was treated with Pefeikang+quadruple therapy,and group B was treated with quadruple therapy.Compared the differences in clinical effects between group A and group B.Results The total effective rate of treatment in group A was 80.0%,which was higher than that in group B by 57.5%,the difference was statistically significant(χ^(2)=4.713,P<0.05).The Hp eradication rate of group A was 85.0%,which was higher than that of group B 65.0%.the difference was statistically significant(χ^(2)=4.267,P<0.05).Before treatment,the gastric mucosal tissue TNF-αof group A and group B were(1.47±0.31)ng/mL and(1.49±0.33)ng/mL,respectively.The difference was not statistically significant(t=0.279,P>0.05);After treatment,gastric mucosal tissue TNF-αin group A and group B were(0.66±0.15)ng/mL and(1.03±0.26)ng/mL,respectively,and the difference was statistically significant(t=7.795,P<0.05).Conclusion Patients with chronic gastritis have a better effect on the treatment of Pefeikang+quadruple therapy,and can increase the Hp eradication rate and improve the gastric mucosal tissue TNF-α,which is worthy of clinical application and promotion.